Akero Therapeutics (AKRO) said Monday that a phase 2b study of its lead product candidate efruxifermin showed a "statistically significant" reversal of compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis, or MASH.
The company said that among patients with baseline and week 96 biopsies, 39% of those treated with efruxifermin showed reversal of cirrhosis without worsening MASH, compared with 15% for the placebo group. In the intent-to-treat group, 29% of patients treated achieved reversal, compared with about 12% for placebo, the company added.
Efruxifermin was well-tolerated, with no deaths in the treatment groups and most side effects being mild, transient, and gastrointestinal in nature, according to Akero.
The company said it is advancing its evaluation of efruxifermin in an ongoing phase 3 trial.
The company's shares soared past 115% in recent Monday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。